Ro60-0175 (1 mg/kg; s.c.) preserves the regularity of responding seen in control animals in drug-treated group, but drug-treated animals reach their break-points earlier[1].
Ro60-0175 (0.3, 1, and 3 mg/kg; s.c.) significantly reduces responding on the active lever in the reinstatement group[1].
Ro60-0175 (0.5 mg/kg SB242084; 1 mg/kg Ro60-0175; s.c.; i.p.) reduces responding compared to vehicle in the reinstatement group, and that this effect is prevented by pretreatment with SB242084. For responding on the inactive lever, there are no significant main effects or interactions[1].
| Animal Model: | Adult male Sprague-Dawley rats (280-320 g)[1] |
| Dosage: | 1 mg/kg |
| Administration: | s.c. |
| Result: | Preserved the regularity of responding seen in control animals in drug-treated group, but drug-treated animals reached their break-points earlier. |
| Animal Model: | Adult male Sprague-Dawley rats (280-320 g)[1] |
| Dosage: | 0.5?mg/kg (SB242084), 1?mg/kg (Ro60-0175) |
| Administration: | s.c. (Ro60-0175), i.p. (SB242084) |
| Result: | Reduced responding for cocaine and effect was reversed by SB242084. |
| Animal Model: | Adult male Sprague-Dawley rats (280-320 g)[1] |
| Dosage: | 0.3, 1, and?3 mg/kg (Ro60-0175), 1?mg/kg (yohimbine) |
| Administration: | s.c. (Ro60-0175), i.p. (yohimbine) |
| Result: | Showed yohimbine treatment alone increased responding relative to vehicle injection, and the response was attenuated dose dependently by Ro60-0175. |
| Animal Model: | Adult male Sprague-Dawley rats (280-320 g)[1] |
| Dosage: | 0.5 mg/kg (SB242084), 1?mg/kg (Ro60-0175), 1?mg/kg (yohimbine) |
| Administration: | s.c. (Ro60-0175), i.p. (yohimbine), i.p. (SB242084) |
| Result: | Ro60-0175 reduced responding and that this effect was prevented by SB242084 pretreatment. |
